Geriatrics addresses the health needs of older adults, focusing on frailty, dementia, falls, and chronic disease management.
Send us all your questions or requests, and our expert team will assist you.
To comprehend the magnitude of macular degeneration and the logic behind regenerative interventions, one must understand the microscopic anatomy of the macula. The retina is a multi-layered sensory tissue lining the back of the eye, often compared to the film in a camera. The macula is located at the optical center of the retina and contains the fovea, a slight depression where visual acuity is highest. This region is densely packed with cone photoreceptors, the cells responsible for color vision and high-resolution detail.
The survival and function of these photoreceptors are entirely dependent on a monolayer of support cells known as the Retinal Pigment Epithelium. The Retinal Pigment Epithelium acts as a nurse cell layer, performing vital functions that sustain the neural retina.
In macular degeneration, the primary failure often originates in this support layer. As the Retinal Pigment Epithelium cells age or succumb to oxidative damage, they fail to support the overlying photoreceptors. When the support cells die, the photoreceptors inevitably follow, leading to the blind spots characteristic of the disease. Regenerative medicine targets this specific dependency, operating on the premise that if the Retinal Pigment Epithelium can be rejuvenated or replaced via stem cell transplantation, the photoreceptors can be preserved or rescued.
There are two main types of macular degeneration, based on whether or not abnormal blood vessels grow in the retina. Knowing the difference is important for choosing the right treatment, especially when considering regenerative therapies and when to use them.
The dry form is the most common presentation, accounting for the vast majority of cases. The slow, progressive atrophy of the Retinal Pigment Epithelium and photoreceptors characterizes it. Clinically, it is marked by the presence of drusen. In its advanced stages, it manifests as Geographic Atrophy, where large areas of the retina waste away, leaving well-demarcated regions of blindness.
The wet form is less common but more serious, causing most cases of severe vision loss. It often develops from the dry form. In wet macular degeneration, the retina does not get enough oxygen and releases more Vascular Endothelial Growth Factor, a protein that causes new, weak blood vessels to grow from the choroid into the retina. This process is called choroidal neovascularization.
Drusen are yellow deposits found under the retina and are a key sign of macular degeneration. Made of fats and proteins, they help doctors judge the health of the eye. Classifying drusen is important for understanding a patient’s risk.
Using stem cell science in eye care is a major change. The eye is less likely to reject transplanted tissue than other organs, so it is a good target for regenerative treatments. Researchers are working on making Retinal Pigment Epithelium cells from human embryonic stem cells or induced pluripotent stem cells. These lab-grown cells can be made without the genetic problems that caused the disease in the first place.
The goal is not merely to slow the disease, as with vitamin supplementation or anti-VEGF drugs, but to reconstitute the anatomy. Surgeons are exploring techniques to implant these cells, either as a suspension or as a monolayer on a bio-engineered scaffold, directly under the retina. Once implanted, these cells are expected to integrate with the host tissue, resume photoreceptor functions, and prevent further vision loss. This biological restoration stands in contrast to prosthetic approaches, offering a more natural physiological solution.
Regenerative medicine also uses helpful substances released by stem cells. Even if the new cells do not fully join with the retina, they can still support the patient’s own cells and help them survive longer. This is called the paracrine effect. This approach shows how complex and promising modern regenerative eye care can be.
Send us all your questions or requests, and our expert team will assist you.
The macula is a small, central part of the retina that lets us see colors and fine details clearly. The outer parts of the retina are better at noticing movement and seeing in low light, but they do not have as many cone cells as the macula. Because the macula is needed for tasks like reading and recognizing faces, its damage has a big effect on daily life.
The Retinal Pigment Epithelium acts as a support system for the photoreceptor cells that sense light. It brings in nutrients, clears away waste, and absorbs extra light. In macular degeneration, these support cells are often damaged first by stress and waste buildup. When they die, the photoreceptors soon die as well, causing vision loss.
Geographic Atrophy is the late stage of dry macular degeneration, where retinal cells slowly die, leading to blind spots. Choroidal Neovascularization is the main feature of wet macular degeneration, with new, leaky blood vessels growing under the retina. Atrophy happens slowly, while neovascularization is fast and can cause fluid leaks and scarring.
Stem cells, especially induced pluripotent stem cells, can be turned into retinal pigment epithelium cells. Scientists grow these cells in the lab and then transplant them into the eye to replace the damaged ones. The goal is to rebuild the support layer for photoreceptors, stop vision loss from getting worse, and possibly bring back some vision where the retina is still healthy.
Genetics is important in macular degeneration, and certain gene changes can raise the risk by affecting the immune system. However, the disease is not only genetic. It is also shaped by factors like smoking, diet, light exposure, and aging. How and when the disease develops depends on both a person’s genes and their lifestyle.
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)